Navigation Links
The KonLin Letter Issues Featured Stock Update on Nuvilex, Inc. in Its September 2009 Edition
Date:9/3/2009

CHERRY HILL, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), today announces that The KonLin Letter has published a stock update featuring Nuvilex, Inc. in its September 2009 issue. As stated in The KonLin Letter, its publisher Mr. Konrad Kuhn compared the company to a "phoenix rising from the ashes," and went on to further state that owning shares of Nuvilex at these levels is similar to "owning an option without an expiration date with unlimited upside potential." Mr. Kuhn also reiterated his aggressive Buy recommendation of the Company's shares.

The KonLin Letter, a 25-year-old investment advisory newsletter noted for its fundamental and technical analysis of individual stocks and market movements, does not accept compensation for its analyses of selected companies. The report includes a review of the latest developments of the Company; its market position and potential advantages, along with fundamentals and statistical analysis.

The featured stock update highlighted the Company's various products with a focus on its current, most-exciting product - Last Shot Hangover Remedy(TM) - with anticipated sales to achieve $5M. OraPhyte(TM), the Company's product created to control and eradicate plant parasitic nematodes, is in testing at Louisiana State University with continuing business development discussions with a Fortune 100 company and two private companies.

The KonLin Letter reported that Nuvilex, Inc. has secured the necessary non-dilutive financing to insure the company has sufficient funds for short-term marketing and sales goals and to conclude its current business development opportunities, partnership and out-licensing negotiations. Further, the company has opportunities to license some of its technology or partner with major worldwide corporations, which could also significantly enhance shareholder value.

The independent opinions expressed in The KonLin Letter are those solely of Mr. Konrad Kuhn. Nuvilex, Inc. has not paid for this report, but is pleased to have such a well-respected, time-tested publication follow the company.

Questions pertaining to The KonLin Letter's featured stock update on Nuvilex, Inc. can be directed to The KonLin Letter via its website, www.konlin.com or by calling the publication at (631) 744-8536.

About Kon-Lin Research & Analysis Corp.

The KonLin Letter, www.KonLin.com, chooses low-priced stocks to analyze, with an emphasis on emerging growth and special situations poised for explosive price appreciation. The KonLin Letter has constantly been one of the leading publications on Wall Street. It has been rated one of the best performing market letters in the nation, offering a unique service that each month recommends five low-priced selections, including a featured stock of the month.

About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy, a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen, which promotes a healthy glucose metabolism; Cinnechol, designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink(R), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink(R). In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit www.nuvilex.com for additional information on the Company.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Investor Relations Contacts:

    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Press Contact:

    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. How Best to Treat Preschoolers With ADHD? The Harvard Mental Health Letter Discusses the Options
2. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
3. Specialty Blades, Inc. Announces Letter of Intent to Acquire Popper and Sons
4. AISHealth.com Introduces Three New Free Services: Health Business Daily Newsletter, Health Business Meeting Calendar, and Health Care Job Openings
5. TeamStaff Receives A Letter of Reprimand From Nasdaq; No Further Action Contemplated
6. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
7. Fighting the Gassy Effects of Good Eating, From the Harvard Health Letter
8. Healthy Living Made Easy with New Diabetes Foodsmart e-Newsletter
9. Cautious Optimism for New Alzheimers Medications, Reports the Harvard Mental Health Letter
10. Mirixa Debuts RxFYI - a Free Pharmacy-Published Health eNewsletter Building Patient Loyalty and Generating Revenue
11. Long Term Care Newsletter Debuts, Published by LTC Financial Partners; Advice on Living Better, Not Just Longer, With Financial Protection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... access for customers and employees that are both engaging and easy to use. ... Smart Technology, the software company revealed today its plans to roll out new ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, ... organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among the ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016   Hudes Laser ... December featuring the multi-wavelength Astanza Trinity laser and ... specializes in laser tattoo removal, IPL hair removal, ... ultrasound therapy. Hudes Laser Aesthetica is setting high ... and promises to deliver effective, long-lasting ...
(Date:12/9/2016)... OSAKA, Japan , Dec. 9, 2016 ... ; President & Representative Director, CEO: Dr. ... with amyotrophic lateral sclerosis (ALS) given edaravone intravenously in ... functional loss as measured by the ALS Functional Rating ... th International Symposium on ALS/MND in ...
(Date:12/9/2016)... 9, 2016  Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced ... Phase 2b trial evaluating treatment with intepirdine (RVT-101), ... donepezil plus placebo in people with mild-to-moderate Alzheimer,s ... intepirdine to treatment was associated with reduced progression ...
Breaking Medicine Technology: